
Diane Simeone, MD, director of Moores Cancer Center and professor of surgery at UC San Diego School of Medicine.
“Being a Comprehensive Cancer Center represents a high level of performance across multiple domains, including the depth and strength of scientific discoveries that ultimately contribute to the understanding of cancer biology, the development of new therapeutics and diagnostics, and ways to study patients to improve the quality of their lives,” said Diane Simeone, MD, director of Moores Cancer Center and professor of surgery at UC San Diego School of Medicine.
“The renewal of the Cancer Center Support Grant is testament to the far-reaching impact of Moores Cancer Center on the future of cancer care,” said Vice Chancellor for Health Sciences John M. Carethers, MD. “The center is both a driver of medical innovation and a lifeline for our patients, a cornerstone of health for the entire San Diego community and beyond.”
Thanks to ongoing funding from the CCSG, MCC is now among the fastest in the country to open clinical trials evaluating cutting-edge therapies for common and rare cancers, with multidisciplinary disease teams responsible for reviewing and bringing these trials to patients.
“We are the leading experts across a number of different cancer types in interventional clinical trials, including prostate cancer, breast cancer, pancreatic cancer, liver cancer, leukemias and brain cancers,” said Simeone. “We’ve nearly tripled our interventional clinical trials over the past several years, bringing more promising therapies to patients quickly, and that’s what we focus on day in and day out.”